Reports

Accenture delivered revenues of $16.7 billion in Q2 FY25, reflecting 5% year-over-year growth in USD. The company reported EPS of $2.82 and non-GAAP EPS increased by 2%. Operating margin expanded to 13.5%. New bookings totaled $20.9 billion, including $1.4 billion in generative AI bookings.

• Revenues reached $16.7 billion, up 5% year-over-year.
• EPS came in at $2.82, showing a 7% increase.

PDD Holdings delivered robust results in Q4 2024, with total revenue reaching $15.15 billion, an increase of 24% year-over-year. The company reported net income of $3.76 billion and operating income of $3.51 billion. Non-GAAP EPS stood at $2.76 per ADS, reflecting continued growth driven by increased revenue from both transaction services and online marketing services.

• Revenue increased 24% YoY to $15.15 billion.
• Net income rose 18% YoY to $3.76 billion.

Nike's third-quarter fiscal 2025 results showed a 9% year-over-year decline in revenue to $11.27 billion, driven by lower sales across all regions. Net income fell 32% to $794 million, and gross margin contracted to 41.5%. The company's diluted EPS was $0.54, while non-GAAP EPS excluding restructuring charges was not applicable this quarter. Operating income also declined significantly.

• Revenue decreased by 9% year-over-year to $11.27 billion.
• Net income dropped 32% to $794 million.

Micron delivered second quarter fiscal 2025 revenue of $8.05 billion and GAAP net income of $1.58 billion. Non-GAAP EPS came in at $1.56, exceeding expectations, supported by robust demand in AI markets and data center DRAM sales. The company ended the quarter with $9.60 billion in cash and marketable investments and anticipates record quarterly revenue in the next quarter.

• Revenue reached $8.05 billion, up from $5.82 billion a year ago.
• GAAP net income was $1.58 billion, with diluted EPS of $1.41.

FedEx delivered third quarter fiscal 2025 revenue of $22.2 billion, with GAAP net income of $910 million and diluted EPS of $3.76. Adjusted EPS reached $4.51, supported by higher base yields, cost reduction initiatives, and increased volumes at Federal Express. Despite facing a compressed peak season and severe weather events, FedEx completed $500 million in share repurchases and maintained solid financial performance.

• Revenue totaled $22.2 billion, up from $21.7 billion in the prior year.
• GAAP net income was $910 million, with diluted EPS of $3.76.

Lennar posted total revenues of $7.63 billion in Q1 2025, with net earnings of $520 million and EPS of $1.96. Home deliveries increased by 6% year-over-year to 17,834 homes. The company maintained a gross margin on home sales of 18.7% and SG&A expenses at 8.5% of home sales revenue. New orders increased slightly by 1% to 18,355 homes, reflecting continued demand despite affordability challenges.

• Total revenues reached $7.63 billion, up from $7.31 billion last year.
• Delivered 17,834 homes, a 6% year-over-year increase.

Darden Restaurants reported Q3 2025 revenue of $3.16 billion, with net income of $323.7 million and EPS of $2.74. Adjusted EPS reached $2.80, a 6.9% increase year-over-year. The company's performance was bolstered by strong holiday and Valentine’s Day sales across several brands.

• Total revenue increased 6.2% to $3.16 billion.
• Net income totaled $323.7 million, up from $313.4 million last year.

FactSet delivered solid Q2 2025 results with revenue growth of 4.5% year-over-year, an increase in both GAAP and adjusted EPS, and higher free cash flow. Organic ASV also grew by 4.1%, showing sustained demand from buy-side clients.

• Revenue reached $570,660,000, up 4.5% year-over-year.
• GAAP diluted EPS increased by 3.0% to $3.76.

Jabil reported Q2 FY25 revenue of $6.73 billion, slightly down from the previous year. GAAP EPS came in at $1.06, while non-GAAP core diluted EPS was $1.94. Net income decreased to $117 million, and operating income was $245 million. The company highlighted strength in key end-markets despite ongoing macroeconomic and geopolitical challenges.

• Revenue reached $6.73 billion, a slight decline year-over-year.
• Net income fell to $117 million from $927 million a year ago.

In Q4 2024, H World Group reported revenue of $825 million, representing a 7.8% year-over-year increase. However, net income dropped sharply to $7 million, primarily driven by foreign exchange losses and tax impacts. Adjusted EBITDA reached $171 million, up from $158 million in the prior year. The company demonstrated strong growth in its manachised and franchised hotel segment, with revenue increasing by 24% year-over-year.

• Revenue increased 7.8% year-over-year to $825 million, exceeding guidance.
• Net income declined to $7 million due to FX losses and higher tax expenses.

In Q4 2024, Zeekr achieved total revenues of $3,120,552,000, marking a 39.2% year-over-year increase. Gross profit surged to $591,355,000 with a 19.0% gross margin. The company reduced its net loss to $112,419,000, down from $2,937,919,000 a year ago. Strong vehicle sales and improved vehicle margin were key drivers of performance.

• Total revenues grew 39.2% YoY to $3.12 billion.
• Vehicle sales reached $2.64 billion, up 82.2% YoY.

Commercial Metals Company reported Q2 2025 revenue of $1.75 billion, with net income of $25.47 million and EPS of $0.22. Adjusted earnings per share were $0.26. The company faced margin pressures in North America but benefited from improved market conditions in Europe and steady growth in Emerging Businesses.

• Revenue was $1.75 billion, stable compared to the prior year.
• Net income reached $25.47 million, significantly down from $85.85 million last year.

Academy Sports + Outdoors posted Q4 2024 revenue of $1.68 billion, a 6.6% decrease year-over-year. GAAP diluted EPS came in at $1.89, while adjusted diluted EPS was $1.96. Net income was $133.63 million and operating income reached $154.70 million. The company opened five new stores and reported a 3.0% decline in comparable sales for the quarter.

• Revenue for Q4 2024 was $1.68 billion, down 6.6% year-over-year.
• Net income decreased 20.6% to $133.63 million.

In Q4 2024, VEON achieved total revenues of $998 million, representing a 4.7% year-over-year increase. EBITDA grew to $408 million, up 11.3% from the previous year. The company reported a net profit of $93 million for the quarter. Strong direct digital revenue growth and increased 4G user penetration were key performance drivers.

• Total revenue increased by 4.7% YoY to $998 million.
• EBITDA rose by 11.3% YoY, reaching $408 million.

Kindercare achieved revenue of $646.96 million in Q4 2024, representing a 4.7% increase compared to the same quarter last year. Despite higher revenues and strong growth in before- and after-school programs, the company reported a net loss of $133.58 million, largely attributed to one-time equity-based compensation expenses related to the IPO. Adjusted net income reached $10.7 million, and adjusted EBITDA was $66 million.

• Q4 2024 revenue grew by 4.7% to $646.96 million.
• Reported a net loss of $133.58 million due to one-time compensation charges.

Planet Labs delivered a strong fourth quarter with a 5% year-over-year increase in revenue to $61.6 million. The company achieved record gross margins, reduced its operating losses, and reported its first adjusted EBITDA profit. Key customer wins and product advancements supported growth, while recurring revenue remained a core strength.

• Q4 revenue increased by 5% year-over-year to $61.6 million.
• Net loss for the quarter was $35.2 million, impacted by warrant liability changes.

In Q4 2024, ARS Pharmaceuticals generated total revenue of $86,600,000, which included $6,700,000 in net product revenue from neffy sales in the U.S. and $73,500,000 from collaboration agreements. The company reported net income of $49,900,000 and diluted earnings per share of $0.48. Operating expenses remained controlled, with a focus on commercialization efforts for neffy.

• Total revenue in Q4 2024 was $86.6 million, driven by collaboration payments and product sales.
• Net product revenue from neffy sales in the U.S. reached $6.7 million.

Shoe Carnival delivered Q4 2024 results with net sales of $262.9 million and adjusted EPS of $0.54. The company demonstrated strong performance through contributions from its Shoe Station and Rogan's acquisition, although comparable store sales fell by 6.3%. Operating income was $14.0 million, supported by efficiency gains and synergy captures.

• Q4 2024 net sales were $262.9 million, up from $260.0 million adjusting for the prior year’s extra week impact.
• Adjusted EPS for Q4 2024 came in at $0.54, slightly below the $0.59 from the previous year.

Luminar exceeded expectations in Q4 2024 with $22.48 million in revenue, a 45% increase quarter-over-quarter. The company achieved a positive gross profit and continued to ramp production for key automotive partners like Volvo. Significant cost reductions and restructuring initiatives improved operational efficiency, although net losses remained.

• Revenue grew 45% quarter-over-quarter to $22.48 million.
• Achieved positive GAAP gross profit of $12.48 million.

Torrid posted net sales of $275.56 million in Q4 2024, a 6.1% decrease year-over-year due to lower sales and the absence of last year's 53rd week. The company reported a net loss of $3.0 million and adjusted EBITDA of $16.7 million, exceeding guidance. Gross profit margin was 33.6%, down 90 basis points, primarily driven by lower sales volumes.

• Q4 net sales declined by 6.1% to $275.56 million.
• Net loss narrowed to $3.0 million compared to $4.1 million last year.

In Q4 2024, Caleres reported net sales of $639.2 million, down 8.3% year-over-year. Adjusted earnings per diluted share were $0.33, with gross profit at $275.1 million and gross margin of 43%. The Famous Footwear segment saw declines while the Brand Portfolio maintained solid performance. Despite challenges, the company remains optimistic with strategic plans for 2025.

• Q4 net sales totaled $639.2 million, a decline of 8.3% year-over-year.
• Gross margin came in at 43.0%, down 80 basis points compared to Q4 2023.

Autolus posted a Q4 net loss of $27.6 million with $29,000 in revenue and an EPS of -0.09. The quarter reflected ongoing investments into commercialization and pipeline development ahead of broader regulatory milestones.

• Net loss of $27.6 million in Q4
• Revenue of $29,000 in the quarter

Scholastic achieved revenue of $335.4 million in Q3 2025, a 4% increase year-over-year. The company saw strong performance in Children's Book Publishing and Distribution, particularly through School Book Fairs and Clubs, as well as contributions from the 9 Story Media Group. Despite a net loss of $3.6 million, adjusted EBITDA turned positive at $6.0 million, reflecting improved operational efficiencies.

• Q3 2025 revenue increased 4% year-over-year to $335.4 million.
• Adjusted EBITDA improved to $6.0 million from a loss of $7.2 million last year.

Gambling.com Group delivered Q4 2024 revenue of $35.31 million, up 9% year-over-year. Net income attributable to shareholders rose to $7.93 million, with diluted EPS of $0.23. Adjusted net income reached $12.17 million, and adjusted diluted EPS was $0.35. The company showed solid operating cash flow and strong margin expansion.

• Q4 revenue grew 9% year-over-year to $35.31 million.
• Net income for the quarter was $7.93 million, with a net income margin of 22%.

Ouster achieved $30.09 million in revenue for Q4 2024, marking a 23% year-over-year increase. The company shipped over 4,800 sensors and reported a GAAP gross margin of 44%, significantly higher than the prior year. Net loss narrowed to $23.74 million, driven by higher revenue, favorable product mix, and lower legacy inventory costs.

• Revenue reached $30.09 million, up 23% year-over-year.
• Shipped over 4,800 sensors for revenue in the quarter.

Runway Growth achieved total investment income of $33.8 million and net investment income of $14.6 million, or $0.39 per share, for Q4 2024. The company reported a dollar-weighted annualized yield on debt investments of 14.7% and made $80.1 million in new funded investments during the quarter. Net realized losses were significantly reduced compared to the prior year, and net assets per share increased to $13.79.

• Total investment income was $33.8 million for Q4 2024.
• Net investment income totaled $14.6 million, or $0.39 per share.

Lands' End posted Q4 2024 revenue of $441.66 million, down 14.2% year-over-year due to product line transitions and reduced promotional activity. The company reported net income of $18.52 million and operating income of $36.95 million. EPS came in at $0.59, and adjusted EPS was $0.57, reflecting operational improvements and margin expansion.

• Q4 2024 revenue declined 14.2% year-over-year to $441.66 million.
• Net income reached $18.52 million, compared to a net loss of $8.62 million in Q4 2023.

Titan Machinery posted Q4 2025 revenue of $759.92 million, down 10.8% year-over-year. The company reported a net loss of $43.76 million and an adjusted net loss of $44.89 million. EPS came in at a loss of $1.93, with adjusted diluted EPS at a loss of $1.88. Adjusted EBITDA was negative $46.02 million as the company accelerated inventory reductions in a softer demand environment.

• Q4 2025 revenue was $759.92 million, down 10.8% year-over-year.
• Net loss totaled $43.76 million compared to net income of $23.96 million in Q4 2024.

Monte Rosa Therapeutics delivered a strong Q4 2024, achieving $60.6 million in collaboration revenue and net income of $13.4 million. The company reported significant progress in its pipeline, particularly with MRT-6160 and MRT-2359, and ended the quarter with a robust cash position to support operations into 2028.

• Reported Q4 collaboration revenue of $60.6 million.
• Achieved net income of $13.4 million, compared to a net loss in the prior year quarter.

Amprius delivered $10.63 million in revenue for Q4 2024, representing a 170% year-over-year increase. The company achieved record product shipments, with 77% of revenue coming from outside the United States. Although the company reported a net loss of $11.42 million, gross margin significantly improved compared to the previous year, reflecting the ramp-up of higher-margin product lines.

• Q4 2024 revenue increased 170% year-over-year to $10.63 million.
• Product revenue surged to $10.3 million, up nearly 1,000% from Q4 2023.

In Q4 2024, Designer Brands reported net sales of $713.6 million, a 5.4% decline year-over-year. Despite the decline in sales and a reported net loss of $38.2 million, comparable sales increased by 0.5%, reflecting progress from strategic initiatives. Gross margin improved to 39.6%.

• Net sales in Q4 2024 decreased by 5.4% to $713.6 million.
• Reported net loss attributable to Designer Brands was $38.2 million, with a loss per diluted share of $0.80.

Verastem reported a significant net loss in Q4 2024 due to higher expenses and fair value adjustments, while advancing regulatory milestones and clinical development. The company ended the quarter with strong liquidity bolstered by refinancing and equity issuance.

• Q4 2024 net loss was $64,550,000, compared to $27,368,000 in Q4 2023.
• Non-GAAP adjusted net loss for Q4 2024 was $29,347,000, or $0.60 per share.

Gold Royalty achieved record revenue of $3.36 million in Q4 2024, supported by 1,445 Gold Equivalent Ounces (GEOs). The company reported positive operating cash flow of $1.26 million and adjusted EBITDA of $1.24 million. Despite a net loss of $3.19 million, the company remains positioned for significant growth driven by its expanding portfolio and ramp-up of key projects.

• Record revenue of $3.36 million in Q4 2024.
• Generated 1,445 GEOs during the quarter.

Baozun delivered a solid performance in Q4 2024 with $410.2 million in revenue, a 7.7% increase compared to last year. Net income turned positive with $20,000, and non-GAAP net income rose to $6.3 million. Operating income reached $10 million, while non-GAAP operating income was $14.2 million, reflecting improved efficiency and cost optimization measures.

• Revenue grew 7.7% YoY to $410.2 million.
• Net income attributable to shareholders turned positive at $20,000.

Destination XL Group, Inc. reported Q4 2024 sales of $119.2 million, down 13.1% from the previous year, with a net loss of $1.3 million or $(0.02) per diluted share. The company reported adjusted net income of $1.0 million or $0.02 per diluted share and adjusted EBITDA of $4.2 million. Gross margin declined to 44.4%, driven by higher occupancy costs due to sales deleverage.

• Q4 revenue declined 13.1% to $119.2 million.
• Net loss of $1.3 million or $(0.02) per diluted share.

Vaxart reported a net loss of $66.9 million for the full year 2024, an improvement from the $82.5 million net loss in 2023. Total revenue for 2024 was $28.7 million, primarily driven by government contracts. The company initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine and continues follow-up for its COVID-19 Phase 2b trial.

• Vaxart's net loss for the full year 2024 was $66.9 million, an improvement from $82.5 million in 2023.
• Total revenue for the full year 2024 was $28.7 million, primarily from government contracts related to BARDA awards.

Adaptimmune reported a Q4 2024 product revenue of $1.2 million from Tecelra, with 3 patients apheresed in 2024 and 10 in Q1 2025, indicating accelerating launch momentum. The company completed a corporate restructure and is implementing additional cost reductions, aiming for profitability by 2027, and ended 2024 with $152 million in total liquidity.

• Tecelra launch momentum is accelerating with 10 patients apheresed in Q1 2025 and 3 in 2024, generating $1.2 million in Q4 product revenue.
• Lete-cel is on track to initiate rolling BLA submission in late 2025, with approval anticipated in 2026, expanding the sarcoma franchise.

TELA Bio delivered a 4% increase in Q4 2024 revenue, supported by higher unit sales, despite facing pressure from lower average selling prices. The company reduced its operating expenses significantly, leading to a narrower net loss compared to the prior year.

• Q4 2024 revenue reached $17,649,000, up 4% year-over-year.
• Gross profit for the quarter was $11,221,000 with a 64% gross margin.

Cellectis (Cibus) achieved revenue growth in Q4 2024 while significantly reducing net loss compared to the prior year. Operational focus included commercialization progress, expanded strategic collaborations, and cost-cutting measures to extend cash runway.

• Revenue for Q4 2024 was $1,212,000, up from $1,103,000 in Q4 2023
• Net loss decreased significantly to $25,804,000 from $277,208,000

Cibus reported a net loss in Q4 2024 while continuing to progress on commercialization and development of key agricultural traits. Revenue remained modest, and the company implemented cost-saving measures and pursued strategic partnerships to strengthen its pipeline.

• Q4 2024 revenue was $1,212,000.
• Net loss for the quarter was $25,804,000, improving from a much larger loss in Q4 2023.

Rockwell Medical delivered strong fourth-quarter results with a notable 12% increase in net sales, improved gross profit, and a narrowed net loss compared to the prior year. The company achieved profitability on an adjusted EBITDA basis and introduced significant agreements positioning it for future growth.

• Net sales for Q4 2024 were $24,700,000, up 12% year-over-year.
• Gross profit for the quarter reached $3,600,000, a 27% increase.

NeueHealth achieved strong fourth-quarter results, with $232.64 million in revenue and net income of $2.52 million. The company reported positive adjusted EBITDA for the fourth consecutive quarter, highlighting the success of its value-driven, consumer-centric care model.

• Q4 2024 revenue was $232,638,000, showing a decrease from the prior year but supported by diversified segments.
• Net income for the quarter reached $2,523,000, reversing a significant loss in Q4 2023.

Immuneering reported a larger net loss in Q4 2024 due to increased R&D expenses as the company advanced its IMM-1-104 clinical program. The company ended the quarter with $36.1 million in cash and cash equivalents and extended its cash runway into 2026.

• Q4 2024 net loss was $18,051,485, or $0.58 per share.
• R&D expenses for the quarter were $14,857,166.

NextCure, Inc. reported a net loss of $55.7 million for the full year ended December 31, 2024, an improvement from the $62.7 million net loss in 2023. The company completed cohort 1 of its LNCB74 Phase 1 trial and expects its current cash resources to fund operations into the second half of 2026.

• Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in February 2025 and plans to initiate backfill cohorts in the second half of 2025.
• Cash, cash equivalents, and marketable securities were $68.6 million as of December 31, 2024, expected to fund operations into the second half of 2026.

In Q4 2024, 22nd Century Group recorded net revenues of $4.02 million, a sequential decline reflecting lower contract manufacturing revenues and VLN® product rebates. The company reported a net loss of $4.25 million and an adjusted EBITDA loss of $3.89 million, highlighting ongoing challenges as they restructure and prepare for product relaunches.

• Net revenues in Q4 2024 were $4,020,000, down from $7,357,000 in Q4 2023.
• Gross loss for the quarter was $1,254,000, improving from a loss of $7,829,000 in the prior year.